Table 1—

Characteristics of the study population

All patients (n = 260)tHcy ≤15 mmol/l (n = 212: 81.5%)tHcy >15 mmol/l (n = 48: 18.5%)P (normal versus high tHcy)
Male/female145/115116/9629/19NS
Age (years)66 ± 1165 ± 1268 ± 110.055
Duration (years)11 ± 810 ± 815 ± 9<0.001
HbAlc (%)6.9 ± 1.56.9 ± 1.56.9 ± 1.4NS
Plasma tHcy (μmol/l)10.5 (2.5–58.1)9.8 (2.5–14.9)20.2 (15.3–58.1)<0.001
Total cholesterol (mmol/l)5.19 ± 1.035.21 ± 1.035.11 ± 1.02NS
HDL cholesterol (mmol/l)1.29 ± 0.371.29 ± 0.371.30 ± 0.38NS
Triglycerides (mmol/l)1.78 ± 1.081.81 ± 1.111.66 ± 0.95NS
Scr (mmol/l)0.09 ± 0.020.09 ± 0.020.11 ± 0.03<0.001
AER (μg/min)6 (1–1,339)6 (1–744)9 (2–1,339)NS
Ccr (calculated ml · min−1 · 1.73 m−2)69.4 (26.9–167.2)72.1 (34.4–167.2)56.3 (26.9–104.4)<0.001
BMI (kg/m2)29 ± 629 ± 629 ± 5NS
Systolic blood pressure (mmHg)140 ± 18140 ± 18140 ± 15NS
Diastolic blood pressure (mmHg)77 ± 1078 ± 1074 ± 100.025
Treatment (%): diet / OHA / insulin / OHA + insulin16/55/22/419/56/21/47/56/30/7NS
Antihypertensive medication (% treated)59.059.658.3NS
Angiotensin-converting enzyme inhibitor (%)31.330.833.3NS
Lipid-lowering therapy (%)4141.141.7NS
Eye complications (%)1715.127.30.054
Ischemic heart disease (%)2119.127.7NS
Cerebrovascular disease (%)9.48.712.5NS
Peripherovascular disease (%)3229.840.9NS
Neuropathy (%)5452.260.0NS
  • Data are n, mean (range), or %. OHA, oral hypoglycemic agent.